

Specific Requirements for certain products in US					
Specific requirements for certain drugs in US					
Ophthalmic Preparations: 21 CFR, part 200, subpart C (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdo40b4a901c8a37735477&gn=div5&view=text&node=21.4.0.1.1.1&idno=21) sets out the requirements for ophthalmic preparations and dispensers.					
Aqueous based drug products for oral inhalation: 21 CFR, part 200, subpart C (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdo40b4a901c8a37735477&gn=div5&view=text&node=21.4.0.1.1.1&idno=21) lays down the requirements for aqueous-based drug products for oral inhalation.					
Thyroid Containing drug preparations: 21 CFR, part 250 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdo40b4a901c8a37735477&gn=div5&view=text&node=21.4.0.1.1.14&idno=21) sets down requirements for thyroid-containing drug preparations intended for treatment of obesity in humans.					
Stramonium Preparations: 21 CFR, part 250 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdo40b4a901c8a37735477&gn=div5&view=text&node=21.4.0.1.1.14&idno=21) sets down requirements for Stramonium preparations.					
Amyl nitrite Inhalant: 21 CFR, part 250 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdo40b4a901c8a37735477&gn=div5&view=text&node=21.4.0.1.1.14&idno=21) sets down requirements for Amyl nitrite inhalant as a prescription drug for human use.					
Amphetamine & Metamphetamine inhalers: 21 CFR, part 250 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdo40b4a901c8a37735477&gn=div5&view=text&node=21.4.0.1.1.14&idno=21) sets down requirements for Amphetamine and methamphetamine inhalers regarded as prescription drugs.					
Drugs containing "coronary vasodilators": 21 CFR, part 250 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdo40b4a901c8a37735477&gn=div5&view=text&node=21.4.0.1.1.14&idno=21) sets down requirements for Drug preparations intended for human use containing certain "coronary vasodilators".					
Gelsemium containing preparations: 21 CFR, part 250 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdo40b4a901c8a37735477&gn=div5&view=text&node=21.4.0.1.1.14&idno=21) sets down requirements for Gelsemium-containing preparations regarded as prescription drugs.					
Potassium Permanganate Preparations: 21 CFR, part 250 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdo40b4a901c8a37735477&gn=div5&view=text&node=21.4.0.1.1.14&idno=21) sets down requirements for Potassium permanganate preparations as prescription drugs.					
Preparations for the treatment of Pernicious anaemia: 21 CFR, part 250 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdo40b4a901c8a37735477&gn=div5&view=text&node=21.4.0.1.1.14&idno=21) sets down requirements for Preparations for the treatment of pernicious anemia.					
Hexachlorophene: 21 CFR, part 250 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdo40b4a901c8a37735477&gn=div5&view=text&node=21.4.0.1.1.14&idno=21) sets down requirements for Hexachlorophene, as a component of drug and cosmetic products.					
Investigational New Drug: 21 CFR, part 312 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdo40b4a901c8a37735477&gn=div5&view=text&node=21.5.0.1.1.3&idno=21) contains procedures and requirements governing the use of investigational new drugs, including procedures and requirements for the submission to, and review by, the FDA of investigational new drug applications (IND's).					
Radio Pharmaceuticals: 21 CFR, part 315 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdo40b4a901c8a37735477&gn=div5&view=text&node=21.5.0.1.1.5&idno=21) apply to radiopharmaceuticals intended for in vivo administration for diagnostic and monitoring use. They do not apply to radiopharmaceuticals intended for therapeutic purposes.					
Orphan Drugs: 21 CFR, part 316 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdo40b4a901c8a37735477&gn=div5&view=text&node=21.5.0.1.1.6&idno=21) sets out the requirements for Orphan Drugs.					
OTC drugs containing alcohol: 21 CFR, part 328 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdo40b4a901c8a37735477&gn=div5&view=text&node=21.5.0.1.1.8&idno=21) sets out requirements for OTC drugs intended for oral ingestion that contain alcohol.					
OTC Human Drugs: 21 CFR, part 328 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdo40b4a901c8a37735477&gn=div5&view=text&node=21.5.0.1.1.9&idno=21) sets out requirements for OTC human drugs.					
OTC antacids: 21 CFR, part 331 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdo40b4a901c8a37735477&gn=div5&view=text&node=21.5.0.1.1.10&idno=21) sets out requirements for OTC antacid products.					
Antiflatulent OTC drugs: 21 CFR part 332 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdo40b4a901c8a37735477&gn=div5&view=text&node=21.5.0.1.1.11&idno=21) sets out requirements for antiflatulent products for over-the-counter human use.					

<p>OTC antifungal drug products: 21 CFR, part 333, subpart B (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&gn=div5&view=text&node=21.5.0.1.1.12&idno=21) lays down the labeling requirements for over-the-counter antifungal drug products.</p>					
<p>OTC antiarrhythmic drugs: 21 CFR, part 335 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&gn=div5&view=text&node=21.5.0.1.1.13&idno=21) sets out the labeling requirements for antiarrhythmic drug products for over-the-counter human use.</p>					
<p>OTC anti-emetic drugs: 21 CFR, part 336 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&gn=div5&view=text&node=21.5.0.1.1.14&idno=21) sets out the labeling requirements for antiemetic drug products for over-the-counter human use.</p>					
<p>OTC night time sleep aid drugs: 21 CFR, part 338 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&gn=div5&view=text&node=21.5.0.1.1.15&idno=21) sets out the labeling requirements for nighttime sleep-aid drug products for over-the-counter human use.</p>					
<p>OTC stimulant drugs: 21 CFR, part 340 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&gn=div5&view=text&node=21.5.0.1.1.16&idno=21) lays down the requirements for stimulant drug products for over-the-counter human use.</p>					
<p>OTC cough, cold, allergy, bronchodilator, and antiasthmatic drug: 21 CFR, part 341 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&gn=div5&view=text&node=21.5.0.1.1.17&idno=21) lays down the labeling requirements for cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use.</p>					
<p>OTC internal analgesic, antipyretic, and antirheumatic drug products: 21 CFR, part 343 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&gn=div5&view=text&node=21.5.0.1.1.18&idno=21) lays down the labeling requirements for internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use.</p>					
<p>Labeling requirements for OTC anorectal drug products: 21 CFR, part 346 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&gn=div5&view=text&node=21.5.0.1.1.20&idno=21) sets out the labeling requirements for anorectal drug products for over-the-counter human use.</p>					
<p>OTC skin protectant drug products: 21 CFR, part 347 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&gn=div5&view=text&node=21.5.0.1.1.21&idno=21) lays down the labeling requirements for skin protectant drug products for over-the-counter human use.</p>					
<p>OTC external analgesic drugs: 21 CFR, part 348 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&gn=div5&view=text&node=21.5.0.1.1.22&idno=21) lays down the labeling requirements for external analgesic drug products for over-the-counter human use.</p>					
<p>OTC Ophthalmic drug products: 21 CFR, part 349 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&gn=div5&view=text&node=21.5.0.1.1.23&idno=21) lays down the labeling requirements for ophthalmic drug products for over-the-counter human use.</p>					
<p>OTC antiperspirant drug products: 21 CFR, part 350 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&gn=div5&view=text&node=21.5.0.1.1.24&idno=21) lays down the labeling requirements for antiperspirant drug products for over-the-counter human use.</p>					
<p>OTC sunscreen drug products: 21 CFR, part 352 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&gn=div5&view=text&node=21.5.0.1.1.25&idno=21) lays down the labeling requirements for sunscreen drug products for over-the-counter human use.</p>					
<p>OTC anticaries drug products: 21 CFR, part 355 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&gn=div5&view=text&node=21.5.0.1.1.26&idno=21) lays down the labeling requirements for anticaries drug products for over-the-counter human use.</p>					
<p>Anthelmintic, cholelystokinetic & deodorant drug products for internal use: 21 CFR, part 357 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&gn=div5&view=text&node=21.5.0.1.1.27&idno=21) lays down the labeling requirements for anthelmintic drug products, cholelystokinetic drug products & deodorant drug products for internal use.</p>					
<p>Drugs for wart removers, ingrown toe-nail relief, corn and callous remover, pediculicide, control of dandruff, seborrheic, dermatitis & psoriasis: 21 CFR, part 358 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&gn=div5&view=text&node=21.5.0.1.1.28&idno=21) lays down labeling requirements for drugs for wart removers, ingrown toe-nail relief, corn and callous remover, pediculicide, control of dandruff, seborrheic, dermatitis & psoriasis.</p>					
<p>Animal Drugs: 21 CFR, part 500, subpart C & D (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&gn=div5&view=text&node=21.6.0.1.1.18&idno=21) lay down the labeling requirements for animal drugs.</p>					

<p>New Animal Drugs:21 CFR, part 510 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&rgn=div5&view=text&node=21:6.0.1.1.5&idno=21) sets out the labeling requirements for new animal drugs.</p>					
<p>New Animal drugs for investigational use: 21 CFR, part 511 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&rgn=div5&view=text&node=21:6.0.1.1.6&idno=21) lays down the requirements for new animal drugs for investigational use.</p>					
<p>Oral Dosage Form New Animal Drugs:21 CFR, part 520 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&rgn=div5&view=text&node=21:6.0.1.1.9&idno=21) sets out labeling requirements for oral dosage form new animal drugs.</p>					
<p>Implantation or injectable dosage form new animal drugs:21 CFR, part 522 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&rgn=div5&view=text&node=21:6.0.1.1.10&idno=21) sets out labeling requirements for implantation or injectable dosage form new animal drugs.</p>					
<p>Ophthalmic and topical dosage form new animal drugs:21 CFR, part 524 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&rgn=div5&view=text&node=21:6.0.1.1.11&idno=21) sets out labeling requirements for ophthalmic and topical dosage form new animal drugs.</p>					
<p>Intramammary dosage forms :21 CFR, part 526 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&rgn=div5&view=text&node=21:6.0.1.1.12&idno=21) sets out labeling requirements for intramammary dosage forms.</p>					
<p>Dosage form new animal drugs:21 CFR, part 529 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&rgn=div5&view=text&node=21:6.0.1.1.13&idno=21) sets out the specifications, approval procedures, conditions of use, indications for use and limitations for certain dosage form new animal drugs.</p>					
<p>Drugs intended for animals:21 CFR, part 530 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&rgn=div5&view=text&node=21:6.0.1.1.14&idno=21) sets out the extralabel use for drugs intended for animals.</p>					
<p>Tolerances for residues of new animal drugs in food :21 CFR, part 556 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&rgn=div5&view=text&node=21:6.0.1.1.15&idno=21) sets out the tolerances for residues of new animal drugs in food.</p>					
<p>Iron containing drugs and supplements (http://www.cfsan.fda.gov/~dms/secgiro2.html) Sets out labeling requirements for iron containing drugs and supplements. For more information on the same please visit: http://www.cfsan.fda.gov/~lrd/ir031017.html</p>					
<p>Human Drugs and biologics: (http://www.fda.gov/cber/gdlns/cntanr.pdf) Container closure systems for packaging human drugs and biologics.</p>					
<p>Biologics products: 21 CFR, part 601 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&rgn=div5&view=text&node=21:7.0.1.1.2&idno=21) sets out the licensing requirements for all biologics products.</p>					
<p>Allergens:21 CFR, part 680 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=8a00a4b294cdc40b4a901c8a37735477&rgn=div5&view=text&node=21:7.0.1.1.9&idno=21) sets out manufacturing standards and testing requirements for allergenic products.</p>					
<p>Drugs for internal use containing mineral oil: 21 CFR, subpart G part 302, (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=b565fa1f9b1765a1df321db5cf50146c&rgn=div5&view=text&node=21:4.0.1.1.2&idno=21#21:4.0.1.1.2.7.1.1) sets out the labeling requirements for drugs for internal use which contain mineral oil.</p>					
<p>Drugs containing wintergreen oil: 21 CFR, part 201, subpart G, part 303, (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=b565fa1f9b1765a1df321db5cf50146c&rgn=div5&view=text&node=21:4.0.1.1.2&idno=21#21:4.0.1.1.2.7.1.1), sets out labeling requirements for drug preparations containing significant proportions of wintergreen oil.</p>					
<p>Tartric acid & barium enema preparations: 21 CFR, part 201, subpart G, part 304 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=b565fa1f9b1765a1df321db5cf50146c&rgn=div5&view=text&node=21:4.0.1.1.2&idno=21#21:4.0.1.1.2.7.1.1) lays down the labeling requirements for Tarric acid & barium enema preparations.</p>					
<p>Isoproterenol inhalation preparations: 21 CFR, part 201, subpart G, part 305, (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=b565fa1f9b1765a1df321db5cf50146c&rgn=div5&view=text&node=21:4.0.1.1.2&idno=21#21:4.0.1.1.2.7.1.1) lays down the labeling requirements for Isoproterenol inhalation preparations.</p>					
<p>Potassium salt preparations for oral ingestion: 21 CFR, part 201, subpart G, part 306 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=b565fa1f9b1765a1df321db5cf50146c&rgn=div5&view=text&node=21:4.0.1.1.2&idno=21#21:4.0.1.1.2.7.1.1) sets out the labeling requirements for potassium salt preparations intended for oral ingestion by man.</p>					

<p>Sodium phosphate: 21 CFR, part 201, subpart G, part 307 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=b565fa1f9b1765a1d321db5cf50146c&rgn=div5&view=text&node=21:4.0.1.1.2&idno=21#21:4.0.1.1.2.7.1.1) lays down the labeling requirements for sodium phosphates.</p>					
<p>Ipecac syrup: 21 CFR, part 201, subpart G, part 308, (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=b565fa1f9b1765a1d321db5cf50146c&rgn=div5&view=text&node=21:4.0.1.1.2&idno=21#21:4.0.1.1.2.7.1.1) sets out the labeling requirements for Ipecac syrup for OTC sale.</p>					
<p>Acetophenetidin: 21 CFR, part 201, subpart G, part 309, (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=b565fa1f9b1765a1d321db5cf50146c&rgn=div5&view=text&node=21:4.0.1.1.2&idno=21#21:4.0.1.1.2.7.1.1) sets out the labeling requirements for acetophenetidin.</p>					
<p>Phenindione: 21 CFR, part 201, subpart G, part 310 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=b565fa1f9b1765a1d321db5cf50146c&rgn=div5&view=text&node=21:4.0.1.1.2&idno=21#21:4.0.1.1.2.7.1.1) sets out the labeling requirements for Phenindione intended for human use.</p>					
<p>Magnesium sulfate heptahydrate: 21 CFR, part 201, subpart G, part 312, (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=b565fa1f9b1765a1d321db5cf50146c&rgn=div5&view=text&node=21:4.0.1.1.2&idno=21#21:4.0.1.1.2.7.1.1) sets out the labeling requirements for Magnesium sulfate heptahydrate.</p>					
<p>Estradiol: 21 CFR, part 201, subpart G, part 313, (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=b565fa1f9b1765a1d321db5cf50146c&rgn=div5&view=text&node=21:4.0.1.1.2&idno=21#21:4.0.1.1.2.7.1.1) sets out the labeling requirements for Estradiol.</p>					
<p>Drug preparations containing salicylates: 21 CFR, part 201, subpart G part 314, (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=b565fa1f9b1765a1d321db5cf50146c&rgn=div5&view=text&node=21:4.0.1.1.2&idno=21#21:4.0.1.1.2.7.1.1) lays down the labeling requirements for drug preparations containing salicylates.</p>					
<p>Drugs for sore throats: 21 CFR, part 201, subpart G, part 315, (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=b565fa1f9b1765a1d321db5cf50146c&rgn=div5&view=text&node=21:4.0.1.1.2&idno=21#21:4.0.1.1.2.7.1.1) lays down the labeling requirements OTC drugs for minor sore throats.</p>					
<p>Drugs with thyroid hormone activity for human use: 21 CFR, part 201, subpart G, part 316 (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=b565fa1f9b1765a1d321db5cf50146c&rgn=div5&view=text&node=21:4.0.1.1.2&idno=21#21:4.0.1.1.2.7.1.1) lays down the labeling requirements for Drugs with thyroid hormone activity for human use.</p>					
<p>Digitalis and related cardiotonic drugs for human use in oral dosage forms: 21 CFR, part 201, subpart G, part 317, (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=b565fa1f9b1765a1d321db5cf50146c&rgn=div5&view=text&node=21:4.0.1.1.2&idno=21#21:4.0.1.1.2.7.1.1) lays down the labeling requirements for Digitalis and related cardiotonic drugs for human use in oral dosage forms.</p>					
<p>Drug products containing or manufactured with chlorofluorocarbons or other ozone-depleting substances: 21 CFR, part 201, subpart G, part 320, (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=b565fa1f9b1765a1d321db5cf50146c&rgn=div5&view=text&node=21:4.0.1.1.2&idno=21#21:4.0.1.1.2.7.1.1) sets out the labeling requirements for drug products containing or manufactured with chlorofluorocarbons or other ozone-depleting substances.</p>					
<p>OTC drug products containing internal analgesic/antipyretic active ingredients: 21 CFR, part 201, subpart G, part 322, (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=b565fa1f9b1765a1d321db5cf50146c&rgn=div5&view=text&node=21:4.0.1.1.2&idno=21#21:4.0.1.1.2.7.1.1) sets out alcohol warning labeling requirements for OTC drug products containing internal analgesic/antipyretic active ingredients.</p>					
<p>Specific Requirements for Electronics in US</p>	<p>Link</p>				
<p>Diagnostic X-Ray system</p>	<p>Elec Machinery\US\TBT_Notifications\TBT\Electricals\TBT000Diagnostic XRay - G.TBT.N.USA.29.doc</p>				
<p>Flight guidance system</p>	<p>Elec Machinery\US\TBT_Notifications\TBT\Electricals\TBT000Flight Guidance Systems - G.TBT.N.USA.75.doc</p>				
<p>Ozone depleting substances</p>	<p>Elec Machinery\US\TBT_Notifications\TBT\Electricals\TBT000Ozone Depleting Substances - G.TBT.N.USA.116.doc</p> <p>Elec Machinery\US\TBT_Notifications\TBT\Electricals\TBT\Ozone Depleting Substances - G.TBT.N.USA.573.doc</p>				
<p>Water heaters, Boilers, Storage tanks</p>	<p>Elec Machinery\US\TBT_Notifications\TBT\Electricals\TBT000Water Heaters - G.TBT.N.USA.367.doc</p>				
<p>Air Conditioners and heat pumps</p>	<p>Elec Machinery\US\TBT_Notifications\TBT\Electricals\TBT\Air Conditioners and Heat Pumps - G.TBT.N.USA.364.doc</p>				
<p>Air Conditioners (HS 8415) and heat pumps (HS 8418)</p>	<p>Elec Machinery\US\TBT_Notifications\TBT\Electricals\TBT\Air Conditioners Heat Pumps - G.TBT.N.USA.3.doc</p>				
<p>Central air conditioner & heat pumps</p>	<p>Elec Machinery\US\TBT_Notifications\TBT\Electricals\TBT\Central Air C Heat Pumps - G.TBT.N.USA.505.doc</p>				
<p>N-Propyl bromide</p>	<p>Elec Machinery\US\TBT_Notifications\TBT\Electricals\TBT\CFCS Substitute - G.TBT.N.USA.45.doc</p>				

